You have full access to this open access article. To provide an overview of the features of patients with medication-related osteonecrosis of the jaw MRONJ and explore recurrence-related factors after surgery. All pathological records of patients diagnosed with osteonecrosis or osteomyelitis of the jaw were reviewed. Only patients who had a history of use of medication related to bone turnover were included.
All demographic and clinical characteristics were collected during review. Univariate and logistic regression analyses were performed to evaluate the associations between risk factors and recurrence. A total of patients were ultimately included. Most patients The breast and prostate were the most common locations of primary tumors in females and males, respectively.
Recurrence occurred in 55 patients at 60 locations. The total recurrence rate was Extensive surgery and flap transfer were strongly related to a lower recurrence risk. When MRONJ is treated with surgical methods, extensive resection and flap transfer can reduce recurrence risk. Six-month follow-up is needed to exclude recurrence after surgery. This study revealed the surgical-related risk factors, such as extensive surgery and flap transfer, when treating MRONJ patients, and 6-month follow-up is needed to detect recurrence.
This could provide clinical guidance for head and neck surgeons. With the progress in immunotherapy and targeted therapy, the survival rate of patients with malignancies has increased significantly, but the incidence of metastatic bone disease is also increasing. Bone is the third most common site of tumor metastasis. Skeletal-related events SREs caused by bone metastasis, such as pathological fracture, decrease quality of life and lead to a poor prognosis [ 1 ].
On the other hand, with the aging of the population, which is becoming one of the biggest issues in the twenty-first century, the incidence of osteoporosis has increased rapidly. Poor bone quality and delayed healing in osteoporosis patients lead to a high risk of fracture. It has been reported that Therefore, to prevent or control SREs, antiresorptive drugs, such as zoledronate or denosumab, are increasingly used.
